Highest-materiality recent filing
Aurinia shareholders elect all five director nominees and approve auditor and say-on-pay at 2026 AGM
Five directors elected: Kevin Tang (96.59%), Jeffrey Bailey (95.33%), Kathy Goetz (96.52%), Craig Johnson (86.50%), Tina S. Nova (86.89%).
Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR
Offer price: $6.955 cash per share plus one contingent value right (CVR).
Aurinia Q1 revenue $77.7M (+24% YoY), EPS $0.25 (+56%); reiterates FY guidance
Net product sales of LUPKYNIS were $73.6M, up 23% YoY.
Aurinia to acquire Kezar for $6.955/share plus CVR; tender offer by April 13
Aurinia (AUPH) to acquire Kezar (KZR) for $6.955 per share in cash plus one non-transferable CVR.
Aurinia appoints Chair Kevin Tang as CEO; entire C-suite replaced effective March 23, 2026
Kevin Tang (Chair) appointed CEO, succeeding Peter Greenleaf; Greenleaf to consult for 3 months at $600/hr.
Aurinia Q4 revenue up 29% to $77.1M, EPS $1.53; guides 2026 LUPKYNIS sales $305M-$315M
LUPKYNIS net product sales for FY 2025: $271.3M, up 25% YoY; Q4 $74.2M, up 29%.
Aurinia Q3 revenue $73.5M (+8%), net income $31.6M; LUPKYNIS sales up 27% YoY, FY guidance raised
Q3 2025 net product sales of LUPKYNIS $70.6M, up 27% YoY; 9-month $197.2M, up 24%.
Aurinia Q2 revenue up 22% to $70M; net income $21.5M; raises FY2025 guidance
Total revenue $70.0M (+22% YoY); net product sales $66.6M (+21%); net income $21.5M vs $0.7M in Q2 2024.
Single doses of aritinercept (5-300 mg s.c.) well tolerated in 61 healthy subjects; no treatment-related Grade ≥3 AEs or SAEs.
Aurinia shareholders approve amended equity plan, elect directors at 2025 AGM
Shareholders approved amended Equity Incentive Plan (20,836,773 Plan Shares) at May 15, 2025 AGM.
Aurinia Q1 revenue $62.5M (+24% YoY); net income $23.3M vs loss of $10.7M; LUPKYNIS sales up 25%
Total revenue $62.5M, up 24% YoY; net product sales of LUPKYNIS were $60.0M (+25% YoY).
Aurinia Q4 2024 net income $1.4M on 33% revenue growth, LUPKYNIS sales up 36% YoY
Q4 total revenue $59.9M (+33% YoY); net product sales $57.6M (+36%); license revenue $2.3M (-18%).
Aurinia Q3 net product rev $55.5M (+36% YoY), net income $14.4M; restructuring cuts 45% workforce
Q3 total net revenue $67.8M; net product revenue $55.5M (+36% YoY); net income $14.4M vs loss of $13.4M a year ago.
Aurinia restructures board: 3 directors resign, Kevin Tang appointed, CEO Greenleaf stays
Board accepted conditional resignations of Daniel Billen, Hector MacKay-Dunn, and Brinda Balakrishnan, effective Sept 9, 2024.
Aurinia Q2 net product revenue $55M (+34% YoY); net income $0.7M, cash flow positive
Net product revenue $55.0M, up 34% YoY; total net revenue $57.2M (+38% YoY).
Aurinia shareholders reject say-on-pay, equity plan; four directors face conditional resignations
CEO Peter Greenleaf and three other directors received less than majority support; conditional resignations submitted under Majority Voting Policy.
Aurinia Q1 net product revenue $48.1M (+40% YoY); expects Q2 cash flow positive
Total net revenue $50.3M (+46% YoY); net loss narrowed to $10.7M ($0.07/sh) from $26.2M.
Aurinia terminates EVP R&D Volker Knappertz in restructuring
Dr. Volker Knappertz, EVP R&D, to be terminated as part of Aurinia's Feb 15 restructuring.
Net product revenue $158.5M (+53% YoY); net loss $78.0M ($0.54/shr) vs $108.2M loss in 2022.
Aurinia preliminary Q4 net product revenue $42M (+49% YoY); FY23 $159M; guides FY24 $200-220M
Preliminary net product revenue Q4 2023: ~$42M, up 49% YoY from $28.3M; full-year ~$159M, up 53% from $103.5M.
Aurinia Q3 net product revenue $40.8M (+60% YoY); narrows FY2023 guidance to $155-160M
Net product revenue $40.8M in Q3, up 60% YoY; 9-month net product revenue $116.2M (+55%).
Aurinia appoints founder Dr. Foster to board; enters cooperation agreement with MKT Capital
Dr. Robert T. Foster appointed to Board effective Sept 21, 2023; term expires at 2024 Annual Meeting.
Aurinia appoints Dr. Karen Smith and Jeffrey A. Bailey to Board; Dr. Daniel G. Billen named Chair
Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board effective August 18, 2023, bringing decades of biopharma leadership experience.
Aurinia Q2 revenue up 47% to $41.5M; raises FY 2023 guidance to $150-160M
Q2 net revenue $41.5M (+47% YoY); net loss narrowed to $11.5M ($0.08 loss per share) from $35.5M ($0.25).
Board initiated exploration of strategic alternatives including sale, merger, or other transaction.
Aurinia shareholders reject say-on-pay, equity plan; two directors resign after low support
Directors Milne and Hagan received less than majority support; resignations submitted per Majority Voting Policy; board to decide.
Aurinia Q1 net revenue $34.4M (+59% YoY); raises 2023 revenue guidance to $135-155M
Net product revenue $34.3M, up from $21.5M in Q1 2022; net loss $26.2M ($0.18/share) vs $37.6M loss a year ago.
Aurinia reports positive renal biopsy data for LUPKYNIS in lupus nephritis
Repeat biopsies from 16 voclosporin and 10 control patients over 18 months.
Aurinia confirms no deposits or accounts at Silicon Valley Bank
Aurinia states it does not hold any deposits, securities, or maintain any accounts at SVB.
Q4 2022 net product revenue $28.3M; FY 2022 net product revenue $103.5M.
Aurinia receives key patent allowance for LUPKYNIS dosing and PTAB terminates IPR challenge
USPTO allowed patent application 17/713,140 for LUPKYNIS dosing with eGFR, extending protection to 2037.
Aurinia reports preliminary Q4 net revenue $28.4M; LUPKYNIS patients up to 1,525
Preliminary Q4 2022 net revenue ~$28.4M, full-year net revenue ~$134.0M.
Aurinia settles patent dispute with Sun Pharma, ends IPR and litigation
Joint motion to terminate IPR on Aurinia's U.S. Patent No. 10,286,036 filed.
Net loss narrowed to $9.0M ($0.06/sh) from $50.3M loss ($0.39/sh) in Q3 2021.
Aurinia EVP Research and CMO depart effective Oct 31, 2022
Robert Huizinga, EVP Research, and Neil Solomons, CMO, mutually agreed to leave Aurinia.
Aurinia receives EU marketing authorization for LUPKYNIS; director Walbert resigns
EC grants marketing authorization for LUPKYNIS (voclosporin) to treat active lupus nephritis in EU, Iceland, Liechtenstein, Norway, and Northern Ireland.
Aurinia Q2 2022 revenue up to $28.2M; net loss narrows to $0.25/share
Q2 net product revenue $28.2M vs $6.6M YoY; six month revenue $49.8M.
Aurinia and CCO Max Colao mutually agree to separation effective July 22
Max Colao, Chief Commercial Officer, will cease employment on July 22, 2022 by mutual agreement.
All nine director nominees elected; for votes ranged from 24.1M (Hagan) to 34.3M (Balakrishnan); broker non-votes 27.9M.
Aurinia Q1 net revenue $21.6M, net loss $37.6M; FY22 guidance reaffirmed
Net product revenue $21.6M (Q1 2021: $0.9M); net loss $37.6M ($0.27/shr) vs $50.4M ($0.40) YoY.
Aurinia Q4 net revenue $23.4M, FY loss $181M; FY22 LUPKYNIS guidance $115-135M
Q4 2021 net revenue $23.4M (60% increase from Q3); full year net revenue $45.6M.
Aurinia reports positive 3-year AURORA 2 data for LUPKYNIS; no new safety signals
eGFR stable over 36 months; +2.7 mL/min vs control from baseline.
Aurinia reports positive long-term safety data from AURORA 2 study of LUPKYNIS in lupus nephritis
116 voclosporin-treated patients showed stable mean eGFR over 36 months; +2.7 mL/min increase from baseline vs control.
Aurinia Q3 revenue $14.7M (+122% QoQ); net loss $50.3M; LUPKYNIS PSF conversion >68%
Net revenue $14.7M vs $29K in Q3 2020; net loss $50.3M ($0.39 per share) vs $42.1M loss a year ago.
Aurinia board adopts annual say-on-pay votes following shareholder advisory vote
Board determined to hold annual say-on-pay votes after 56,605,305 shares (approx. 92% of votes cast) favored a 1-year frequency.
Aurinia licenses novel peptide AUR300 from Riptide for autoimmune/fibrotic diseases; $6M upfront
Global licensing/research pact with Riptide for peptide AUR300 targeting M2 macrophages via CD206 receptor.
Aurinia Q2 2021 revenue $6.6M, 415 LUPKYNIS PSFs, guides FY revenue $40-50M
Net revenue $6.6M (624% growth over Q1 2021); net loss $47.0M ($0.37/share) vs $26.5M loss in Q2 2020.
Aurinia voluntarily delists from TSX effective July 30, 2021; continues on Nasdaq
Delisting from Toronto Stock Exchange effective July 30, 2021; no shareholder approval required.
Effective November 7, 2024, Aurinia issued a press release announcing the appointment of Craig Johnson to the Board of Directors of the Company
Aurinia plans to terminate its employment relationship with Scott Habig.
the Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
Effective September 12, 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as member of the Board.
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
As part of the restructuring that Aurinia Pharmaceuticals Inc. (Aurinia) announced on February 15, 2024, Aurinia plans to terminate its employment relationship with Dr. Volker Knappertz.
In connection with the Cooperation Agreement, Dr. Foster was appointed to the Board, effective September 21, 2023.
On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.
On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.
the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.
Max materiality 0.85 · Median 0.70 · Most common event earnings